These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38919518)

  • 1. Application of Delta T1 maps for quantitative and objective assessment of extent of resection and survival prediction in glioblastoma.
    Laing BR; Prah MA; Best BJ; Krucoff MO; Mueller WM; Schmainda KM
    Neurosurg Pract; 2024 Mar; 5(1):. PubMed ID: 38919518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
    Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
    J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which Parameter Is More Important for the Prognosis of New-Onset Adult Glioblastoma: Residual Tumor Volume or Extent of Resection?
    Xing Y; Wang X
    World Neurosurg; 2018 Aug; 116():e444-e451. PubMed ID: 29753893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.
    Grabowski MM; Recinos PF; Nowacki AS; Schroeder JL; Angelov L; Barnett GH; Vogelbaum MA
    J Neurosurg; 2014 Nov; 121(5):1115-23. PubMed ID: 25192475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ.
    Zeyen T; Böhm L; Paech D; Schäfer N; Tzaridis T; Duffy C; Nitsch L; Schneider M; Potthoff AL; Schneider-Rothhaar JL; Steinbach JP; Hau P; Kowalski T; Seidel C; Krex D; Grauer O; Goldbrunner R; Zeiner PS; Tabatabai G; Galldiks N; Stummer W; Hattingen E; Glas M; Gkika E; Vatter H; Radbruch A; Herrlinger U; Weller J; Schaub C
    Neuro Oncol; 2024 Oct; ():. PubMed ID: 39351820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volumetric Analysis Using Low-Field Intraoperative Magnetic Resonance Imaging for 168 Newly Diagnosed Supratentorial Glioblastomas: Effects of Extent of Resection and Residual Tumor Volume on Survival and Recurrence.
    Fukui A; Muragaki Y; Saito T; Maruyama T; Nitta M; Ikuta S; Kawamata T
    World Neurosurg; 2017 Feb; 98():73-80. PubMed ID: 27989974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automatic estimation of extent of resection and residual tumor volume of patients with glioblastoma.
    Meier R; Porz N; Knecht U; Loosli T; Schucht P; Beck J; Slotboom J; Wiest R; Reyes M
    J Neurosurg; 2017 Oct; 127(4):798-806. PubMed ID: 28059651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
    Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
    J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of reproducibility in MRI quantitative volumetric assessment and its role in the prediction of overall survival and progression-free survival in glioblastoma.
    Blomstergren A; Rydelius A; Abul-Kasim K; Lätt J; Sundgren PC; Bengzon J
    Acta Radiol; 2019 Apr; 60(4):516-525. PubMed ID: 29966430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery.
    Shah AS; Sylvester PT; Yahanda AT; Vellimana AK; Dunn GP; Evans J; Rich KM; Dowling JL; Leuthardt EC; Dacey RG; Kim AH; Grubb RL; Zipfel GJ; Oswood M; Jensen RL; Sutherland GR; Cahill DP; Abram SR; Honeycutt J; Shah M; Tao Y; Chicoine MR
    J Neurosurg; 2021 Aug; 135(2):505-514. PubMed ID: 33035996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extent of Resection Thresholds in Molecular Subgroups of Newly Diagnosed Isocitrate Dehydrogenase-Wildtype Glioblastoma.
    Dono A; Zhu P; Takayasu T; Arevalo O; Riascos R; Tandon N; Ballester LY; Esquenazi Y
    Neurosurgery; 2024 Oct; 95(4):932-940. PubMed ID: 38687046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
    Bloch O; Han SJ; Cha S; Sun MZ; Aghi MK; McDermott MW; Berger MS; Parsa AT
    J Neurosurg; 2012 Dec; 117(6):1032-8. PubMed ID: 23039151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study.
    Bjorland LS; Mahesparan R; Fluge Ø; Gilje B; Dæhli Kurz K; Farbu E
    Neurooncol Adv; 2023; 5(1):vdad126. PubMed ID: 37868696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups.
    Gerritsen JKW; Zwarthoed RH; Kilgallon JL; Nawabi NL; Versyck G; Jessurun CAC; Pruijn KP; Fisher FL; Larivière E; Solie L; Mekary RA; Satoer DD; Schouten JW; Bos EM; Kloet A; Tewarie RN; Smith TR; Dirven CMF; De Vleeschouwer S; Vincent AJPE; Broekman MLD
    Neuro Oncol; 2023 May; 25(5):958-972. PubMed ID: 36420703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Counseling Patients with a Glioblastoma Amenable Only for Subtotal Resection: Results of a Multicenter Retrospective Assessment of Survival and Neurologic Outcome.
    Coburger J; Segovia J; Ganslandt O; Ringel F; Wirtz CR; Renovanz M
    World Neurosurg; 2018 Jun; 114():e1180-e1185. PubMed ID: 29621607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival.
    Orringer D; Lau D; Khatri S; Zamora-Berridi GJ; Zhang K; Wu C; Chaudhary N; Sagher O
    J Neurosurg; 2012 Nov; 117(5):851-9. PubMed ID: 22978537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma surgery with and without intraoperative MRI at 3.0T.
    Napolitano M; Vaz G; Lawson TM; Docquier MA; van Maanen A; Duprez T; Raftopoulos C
    Neurochirurgie; 2014 Aug; 60(4):143-50. PubMed ID: 24975207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy.
    Pessina F; Navarria P; Cozzi L; Ascolese AM; Simonelli M; Santoro A; Tomatis S; Riva M; Fava E; Scorsetti M; Bello L
    Ann Surg Oncol; 2016 Sep; 23(9):3040-6. PubMed ID: 27072998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of removed tumor volume and location on patient outcome in glioblastoma.
    Awad AW; Karsy M; Sanai N; Spetzler R; Zhang Y; Xu Y; Mahan MA
    J Neurooncol; 2017 Oct; 135(1):161-171. PubMed ID: 28685405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.